10 Emerging Combination Therapies for Gastrointestinal Cancers to Watch in 2026

Why Combination Therapies Matter in GI Cancer

The 2026 ASCO Gastrointestinal Cancers Symposium underscored a decisive shift toward biomarker‑driven regimens that pair novel antibodies, targeted small‑molecule inhibitors, and immune checkpoint blockade. Trials such as ILUSTRO (zolbetuximab + mFOLFOX6 + nivolumab for CLDN18.2‑positive gastric cancer) and HERIZON‑GEA‑01 (zanidatamab ± tislelizumab + chemotherapy for HER2‑positive GEJ adenocarcinoma) illustrate how precise molecular selection allows clinicians to match the right drug cocktail to each tumor’s biology.

Synergy emerges when targeted agents weaken oncogenic pathways while immunotherapy reactivates anti‑tumor immunity. The COMMIT trial demonstrated that adding bevacizumab and atezolizumab to FOLFOX trip dMMR/MSI‑H colorectal cancer trip PFS and response rates far beyond atezolizumab alone. Likewise, KRAS G12D inhibition (INCB161734) combined with mFOLFIRINOX produced a 37% objective response rate in pancreatic cancer, showing that even historically “undruggable” mutations can be leveraged when paired with chemotherapy.

Clinically, these combinations translate into meaningful survival gains and improved quality of life. BREAKWATER reported longer overall survival for BRAF V600E‑mutant metastatic colorectal cancer using encorafenib + cetuximab + FOLFIRI, while COMMIT’s triple‑punch regimen extended median PFS to 24.5 months in MSI‑H/dMMR colorectal cancer. Importantly, biomarker‑directed approaches also spare patients from ineffective therapy, reduce unnecessary toxicity, and support durable disease control, ultimately offering a more personalized and tolerable treatment experience for gastrointestinal cancer patients.

Key Oncology Trials and Therapies in GI Cancers 2026

1. ILUSTRO Phase II trial reported a median progression‑free survival of 12.9 months for CLDN18.2‑positive gastric/GEJ cancer using zolbetuximab combined with mFOLFOX6 and nivolumab.
2. CLDN18.2 is expressed in approximately 38% of screened gastric and gastro‑esophageal junction tumors and predicts enhanced antibody‑dependent cellular cytotoxicity when targeted by zolbetuximab.
3. HERIZON‑GEA‑01 Phase III trial showed zanidatamab (dual‑HER2 bispecific) with chemotherapy, with or without tislelizumab, improved progression‑free survival beyond 12 months and cut progression risk by 35% versus trastuzumab‑plus‑chemotherapy in HER2‑positive gastric cancer.
4. The LyRICX Phase II trial of liposomal irinotecan‑based chemotherapy ± nivolumab demonstrated modest progression‑free survival gains and higher disease‑control rates in metastatic esophagogastric adenocarcinoma.
5. COMMIT Phase III trial (mFOLFOX6 + bevacizumab + atezolizumab) achieved a median PFS of 24.5 months in dMMR/MSI‑H metastatic colorectal cancer, far exceeding the ~5‑month PFS of atezolizumab monotherapy.
6. BREAKWATER Phase III established encorafenib + cetuximab + FOLFIRI as a new first‑line standard for BRAF V600E‑mutant metastatic colorectal cancer, delivering an objective response rate of ~60% and median PFS over 12 months.
7. INCB161734, an oral KRAS G12D inhibitor, combined with mFOLFIRINOX or gemcitabine/nab‑paclitaxel produced a 37% objective response rate and 78% disease‑control rate in KRAS G12D‑mutant pancreatic ductal adenocarcinoma.
8. Spevatamig (a CLDN18.2 and CD47 bispecific antibody) plus chemotherapy yielded a 40% objective response rate and 93% disease‑control rate in CLDN18.2‑positive metastatic pancreatic cancer.
9. Mitazalimab, a CD40 agonist antibody, combined with mFOLFIRINOX (OPTIMIZE‑1) achieved a 32.5% objective response rate and a median progression‑free survival of 6.7 months in metastatic pancreatic cancer.
10. The FDA approved zolbetuximab (brand name Vyloy) in October 2024 for advanced gastric and gastro‑esophageal junction adenocarcinoma, improving median overall survival by 2‑3 months when added to standard mFOLFOX6 chemotherapy.

1. Zolbetuximab + mFOLFOX6 + Nivolumab for CLDN18.2‑Positive Gastric/GEJ Cancer

The phase II ILUSTRO trial (LBA284) evaluated a biomarker‑driven triple‑punch regimen—zolbetuximab, mFOLFOX6, and nivolumab—as first‑line therapy for patients with CLDN18.2‑positive gastric or gastro‑esophageal junction adenocarcinoma. CLDN18.2, expressed in roughly 38 % of screened tumors, serves as a predictive biomarker that enriches for high‑activity antibody‑dependent cellular cytotoxicity (ADCC) when zolbetuximab is paired with chemotherapy. In the ILUSTRO cohort, median progression‑free survival reached 12.9 months, with the greatest benefit observed in tumors showing high CLDN18.2 intensity. The combination leverages the cytotoxic backbone of mFOLFOX6, the ADCC‑mediated tumor cell killing of zolbetuximab, and PD‑1 blockade by nivolumab to overcome primary resistance mechanisms. Early safety data were manageable, with nausea, fatigue and hypersensitivity being most common, supporting further development in a phase III trial adding pembrolizumab.

2. Zanidatamab ± Tislelizumab + Chemotherapy for HER2‑Positive Gastric/GEJ Adenocarcinoma

The phase III HERIZON‑GEA‑01 trial (LBA285) evaluated first‑line zanidatamab, a dual‑HER2 bispecific antibody that simultaneously binds two distinct HER2 epitopes, together with standard chemotherapy, with or without the anti‑PD‑L1 agent tislelizumab, versus the conventional trastuzumab‑plus‑chemotherapy backbone in HER2‑positive advanced gastric and gastro‑esophageal junction adenocarcinoma. By engaging two HER2 domains, zanidatamab promotes more complete receptor blockade and enhances antibody‑dependent cellular cytotoxicity compared with trastuzumab alone. Adding tislelizumab aims to amplify antitumor immunity by blocking PD‑L1‑mediated T‑cell inhibition, potentially overcoming intrinsic resistance to HER2‑targeted therapy. Early data suggest a median progression‑free survival exceeding 12 months and a 35 % reduction in risk of progression or death with the zanidatamab‑based regimens, highlighting the promise of integrating dual HER2 targeting and checkpoint inhibition for this molecularly defined patient population.

3. Liposomal Irinotecan‑Based Chemotherapy ± Nivolumab (LyRICX) for Esophagogastric Adenocarcinoma

The phase II LyRICX trial (LBA287) evaluated first‑line treatment for metastatic or unresectable esophagogastric adenocarcinoma using a liposomal irinotecan backbone. Patients were randomized to receive liposomal irinotecan combined with either carboplatin‑based or oxaliplatin‑based chemotherapy, with each arm further split to receive nivolumab or not. The study aimed to determine whether the addition of the PD‑1 inhibitor could improve disease‑control rates compared with chemotherapy alone. Preliminary data suggest that both carboplatin‑based and oxaliplatin‑based combos are tolerable, but the nivolumab-containing cohorts show a modest increase in progression‑free survival and higher overall disease‑control rates. These findings support a biomarker‑driven, chemo‑immunotherapy approach for first‑line management of esophagogastric adenocarcinoma and set the stage for a larger phase III confirmation trial.

4. mFOLFOX6 + Bevacizumab + Atezolizumab (COMMIT) for dMMR/MSI‑H Metastatic Colorectal Cancer

The Phase III COMMIT trial (Abstract 14) evaluated a triple‑punch regimen—mFOLFOX6 chemotherapy, the anti‑angiogenic antibody bevacizumab, and the PD‑L1 inhibitor atezolizumab—as first‑line therapy for patients with deficient mismatch‑repair (dMMR) or microsatellite‑instability‑high (MSI‑H) metastatic colorectal cancer. By pairing a cytotoxic backbone with both vascular blockade and immune checkpoint inhibition, the study aimed to overcome primary resistance to immunotherapy seen in this biologically distinct subgroup. Results showed a striking median progression‑free survival of 24.5 months for the triple‑punch arm, compared with roughly 5 months for atezolizumab monotherapy, underscoring the synergistic benefit of integrating chemotherapy, anti‑angiogenesis, and PD‑L1 blockade in dMMR/MSI‑H disease.

5. Encorafenib + Cetuximab + FOLFIRI (BREAKWATER) for BRAF V600E‑Mutant Metastatic Colorectal Cancer

The phase III BREAKWATER trial (abstract 13) evaluated a biomarker‑driven triple‑drug regimen—encorafenib (a BRAF V600E inhibitor), cetuximab (EGFR blockade), and FOLFIRI chemotherapy—as first‑line therapy for patients with BRAF V600E‑mutant metastatic colorectal cancer (mCRC). Compared with the standard FOLFIRI + bevacizumab backbone, the ENCOR‑CETU‑FOLFIRI combination produced markedly higher objective response rates (≈60 % vs 40 %) and a trend toward longer overall survival, while the chemotherapy backbone (FOLFIRI vs mFOLFOX6) did not affect efficacy. These data support the triple regimen as a new first‑line standard for BRAF‑mutant mCRC, offering a targeted approach that simultaneously blocks the MAPK pathway at two nodes and delivers irinotecan‑based cytotoxicity.

6. INCB161734 (KRAS G12D Inhibitor) + Chemotherapy for KRAS G12D‑Mutant Pancreatic Cancer

The phase I INCB161734 study (abstract 654) evaluated the oral KRAS G12D inhibitor INCB161734 as both a single agent and in combination with standard chemotherapy regimens in patients with KRAS G12D‑mutant pancreatic ductal adenocarcinoma. Monotherapy was administered across dose‑escalation cohorts, while combination arms paired INCB161734 at 1,200 mg daily with either mFOLFIRINOX or gemcitabine/nab‑paclitaxel . The trial demonstrated a promising objective response rate of 37 % and a disease‑control rate of 78 % at the 1,200 mg dose, indicating robust antitumor activity in this historically resistant population. Safety was manageable, with fatigue, nausea, and anemia being the most common adverse events, and grade 3–4 toxicities occurring in roughly 15 % of participants. These data support further development of INCB161734‑based regimens and suggest that KRAS G12D‑directed therapy can meaningfully enhance outcomes when combined with established chemotherapy backbones.

7. Spevatamig (CLDN18.2 & CD47 Targeted) + Chemotherapy for Claudin‑18.2‑Positive Pancreatic Cancer

The TWINPEAK phase II study evaluated spevatamig (PT886), a bispecific antibody that simultaneously targets the tumor‑associated antigen claudin‑18.2 and the “don’t‑eat‑me” signal CD47, in combination with standard chemotherapy for patients with claudin‑18.2‑positive metastatic pancreatic ductal adenocarcinoma. By engaging claudin‑18.2, spevatamig directs immune effector cells to the cancer cells, while CD47 blockade removes the inhibitory signal that normally prevents macrophage‑mediated phagocytosis. This dual‑targeting strategy translated into a robust 40 % objective response rate and a 93 % disease‑control rate, indicating that the combination can achieve meaningful tumor shrinkage and durable disease stabilization in a population that historically responds poorly to chemotherapy alone. The safety profile was manageable, with most adverse events being low‑grade and consistent with the chemotherapy backbone. These results position spevatamig as a promising addition to the therapeutic armamentarium for claudin‑18.2‑positive pancreatic cancer and support further investigation in larger, randomized trials.

8. Mitazalimab (CD40 Agonist Antibody) + mFOLFIRINOX (OPTIMIZE‑1) for Metastatic Pancreatic Cancer

The phase Ib/II OPTIMIZE‑1 trial evaluated the CD40 agonist antibody mitazalimab in combination with the standard mFOLFIRINOX chemotherapy backbone in patients with previously untreated metastatic pancreatic ductal adenocarcinoma. CD40 activation is designed to prime antitumor immunity by converting immunosuppressive myeloid cells into potent antigen‑presenting cells, thereby enhancing T‑cell infiltration and synergizing with cytotoxic chemotherapy. Preliminary results showed an objective response rate of 32.5 % and a median progression‑free survival of 6.7 months, indicating that immune priming before chemotherapy can improve disease control in this historically resistant tumor type.

9. Pembrolizumab + Lenvatinib for Advanced Gastric and GEJ Cancer

The 2025 FDA breakthrough‑therapy designation for the pembrolizumab‑lenvatinib duo reflects early signals of meaningful activity in patients with advanced, HER2‑negative gastric or gastro‑esophageal junction adenocarcinoma. Early‑phase data demonstrate that pairing the anti‑VEGF Tinib with antibody the IL‑L‑‑ checkpoint inhibitor pembrolizumab produces a synergistic anti‑angiogenic and immune‑stimulating effect, translating into higher objective response rates than pembrolizumab alone. In biomarker‑unselected, HER2‑negative cohorts, response rates have risen to the 30‑40 % range, with durable disease control observed in a substantial proportion of patients. These findings support the rationale for further phase‑III evaluation and suggest a new therapeutic option for a population that historically relies on chemotherapy alone.

10. Nivolumab + Ipilimumab (CheckMate 9DW) for Unresectable Hepatocellular Carcinoma

The phase III CheckMate 9DW trial presented a four‑year follow‑up that confirms the durability of the nivolumab + ipilimumab regimen in patients with unresectable hepatocellular carcinoma (HCC). Compared with the standard anti‑angiogenic agents lenvatinib or sorafenib, the dual‑checkpoint blockade delivered a clear overall‑survival advantage: median OS was 23.7 months versus 20.6 months for the control arms, and 38 % of patients remained alive at 36 months, a notable improvement over the 27 %–30 % historical survival rates with lenvatinib or sorafenib. The data underscore the potential of immune‑based strategies to shift the treatment paradigm for advanced HCC, especially for patients who are fit for immunotherapy and have not received prior systemic therapy. Ongoing biomarker analyses aim to identify which tumor‑immune signatures predict the greatest benefit from this combination, paving the way for more personalized treatment approaches.

New Drugs for Bowel Cancer in 2026

The 2026 ASCO Gastrointestinal Cancers Symposium highlighted the phase III BREAKWATER trial, which established a new first‑line standard for BRAF V600E‑mutant metastatic colorectal cancer (mCRC). The regimen combines encorafenib, a BRAF V600E inhibitor, cetuximab (an anti‑EGFR antibody), and fluorouracil‑based chemotherapy (FOLFIRI). In BREAKWATER, this triple‑targeted approach produced a median progression‑free survival of 12‑plus months, a higher overall response rate (≈60 % vs 40 % with standard therapy), and a trend toward improved overall survival, without adding prohibitive toxicity. The FDA granted traditional approval to encorafenib + cetuximab + FOLFIRI in early 2026, expanding on the accelerated approval granted in 2024. This approval gives clinicians a mutation‑specific, biomarker‑driven option that directly targets the MAPK pathway while maintaining chemotherapy backbone efficacy. Consequently, the treatment landscape for bowel cancer now includes a targeted, first‑line alternative for the ~10 % of mCRC patients harboring BRAF V600E, shifting practice away from chemotherapy alone and paving the way for further biomarker‑guided combinations.

Groundbreaking Treatments for Stomach Cancer in 2026

Yes—2026 has brought several breakthrough options for stomach (gastric) cancer that go beyond traditional chemotherapy.

HER2‑targeted bispecifics and ADCs – The phase III HERIZON‑GEA‑01 trial showed that zanidatamab, a dual‑HER2 bispecific antibody, combined with chemotherapy (and optionally tislelizumab) prolonged progression‑free survival and reduced the risk of death compared with standard trastuzumab‑plus‑chemotherapy in HER2‑positive gastroesophageal adenocarcinoma. Early data on trastuzumab‑deruxtecan plus pembrolizumab also demonstrated high response rates after progression on first‑line trastuzumab, underscoring the growing role of HER2‑directed ADCs.

Immune‑checkpoint combinations – Biomarker‑driven immunotherapy is now a cornerstone for gastric cancer. The ILUSTRO Phase II study evaluated zolbetuximab (CLDN18.2‑targeted) together with mFOLFOX6 and nivolumab, achieving a median PFS of 12.9 months in CLDN18.2‑positive disease. Pembrolizumab combined with chemotherapy has improved response rates in HER2‑negative tumors, and MSI‑H/dMMR gastric cancers benefit from pembrolizumab monotherapy or in combination with chemotherapy, producing durable remissions.

Second‑line anti‑angiogenic strategies – After progression, ramucirumab (anti‑VEGFR2) plus paclitaxel remains the standard second‑line regimen, with ongoing trials exploring bevacizumab‑based combos (e.g., atezolizumab + bevacizumab) for intermediate‑stage hepatocellular carcinoma and potentially for gastric cancer. Emerging CD40 agonists and bispecific T‑cell engagers are also being evaluated in later‑line settings, offering new options for refractory disease.

These advances collectively provide a more personalized, effective, and hopeful therapeutic landscape for patients with advanced gastric cancer.

The ‘Miracle’ Drug for Colon Cancer

Dostarlimab, a PD‑1‑inhibitor, has emerged as a breakthrough therapy for colorectal cancers that are mismatch‑repair deficient (dMMR) or microsatellite‑instability‑high (MSI‑H). In early‑phase trials, patients with dMMR/MSI‑H rectal tumors receiving dostarlimab achieved striking response rates, with many experiencing complete clinical responses that allowed them to forgo surgery, radiation, and conventional chemotherapy. This “miracle” effect is driven by the drug’s ability to unleash a robust anti‑tumor immune response in tumors that are highly immunogenic due to their high mutational burden. The therapeutic impact is underscored by real‑world adoption in several European health systems and ongoing expansion in the United States.

What is the new miracle drug for colon cancer?
The new “miracle” drug for colon (colorectal) cancer is dostarlimab, a PD‑1‑inhibitor immunotherapy. It is specifically effective in tumors that are mismatch‑repair deficient (dMMR) or microsatellite‑instability‑high (MSI‑H), a genetic subset accounting for roughly 3‑5 % of rectal cancers. In early clinical trials, patients receiving dostarlimab have achieved complete clinical responses, often allowing them to avoid surgery, radiation, or conventional chemotherapy. The drug has already been adopted as a standard option for eligible patients in Wales and Italy after promising trial data. Ongoing studies in the United States and elsewhere are expanding its use to broader colorectal‑cancer populations.

New Medicine for Gastric Cancer: Zolbetuximab

Zolbetuximab (brand name Vyloy) is the newest targeted therapy approved for advanced gastric and gastroesophageal‑junction (GEJ) adenocarcinoma. It is a first‑in‑class monoclonal antibody that binds claudin‑18.2 (CLDN18.2), a tight‑junction protein over‑expressed in up to 40 % of gastric/GEJ tumors. The FDA granted approval in October 2024 based on the phase 3 SPOTLIGHT and GLOW trials, which demonstrated statistically significant but modest gains when zolbetuximab was added to standard fluoropyrimidine‑oxaliplatin chemotherapy. In those studies, median overall survival improved by 2–3 months and progression‑free survival by 1.4–1.9 months compared with chemotherapy alone. The drug is administered intravenously and is most commonly combined with the mFOLFOX6 regimen (5‑fluorouracil, leucovorin, and oxaliplatin). The main toxicities are nausea, vomiting, and occasional hypersensitivity reactions; prophylactic anti‑emetics, slower infusion rates, and pre‑medication mitigate these effects. Zolbetuximab therefore represents a biomarker‑driven advance, offering a new line of therapy for patients whose tumors express CLDN18.2 and are HER2‑negative.

Updates for Oncology Drugs in 2026

The 2026 FDA oncology landscape features a wave of new approvals, accelerated clear, and breakthrough designations that broaden treatment options across solid tumors and hematologic malignancies. In March 2026, nivolumab (Opdivo) gained its first indication in combination with doxorubicin, vinblastine, and dacarbazine for previously untreated Stage III–IV classical Hodgkin lymphoma. Later that month, the bispecific antibody teclistamab received approval together with daratumumab hyaluronidase‑fihj for relapsed or refractory multiple myeloma after at least one prior therapy line. Accelerated approval arrived on February 26, 2026 for zongertinib (Hernexeos) in HER2‑mutated unresectable or metastatic non‑squamous non‑small‑cell lung cancer, followed by traditional approval on February 24, 2026 for encorafenib (Braftovi) in BRAF V600E‑mutant metastatic colorectal cancer when paired with cetuximab and fluorouracil‑based chemotherapy. Earlier in February, acalabrutinib (Calquence) plus venetoclax was approved for chronic lymphocytic leukemia/small lymphocytic lymphoma, and pembrolizumab (Keytruda) indications expanded to include paclitaxel‑based regimens for platinum‑resistant ovarian, fallopian‑tube, and primary peritoneal carcinomas. These approvals underscore the FDA’s continued emphasis on biomarker‑driven, combination‑therapy strategies and the use of accelerated or breakthrough pathways to bring promising agents to patients more rapidly.

2026 Cancer‑Therapy Landscape Overview

2026 marks a shift toward earlier, biomarker‑driven interventions across gastrointestinal malignancies. Multimodal screening—circulating tumor DNA (ctDNA) assays, AI‑enhanced imaging, and spatial profiling—enables risk stratification before overt disease, guiding neoadjuvant or adjuvant strategies such as the ILUSTRO trial (zolbetuximab + mFOLFOX6 + nivolumab) for CLDN18.2‑positive gastric cancer and the COMMIT study (mFOLFOX6 + bevacizumab + atezolizumab) for dMMR/MSI‑H colorectal cancer.

Emerging modalities are expanding the therapeutic toolbox. PROTACs and selective degraders (e.g., KRAS G12D degrader Setidegrasib) are entering early‑phase trials, offering a way to eliminate “undruggable” KRAS mutants. Bispecific antibodies—zanidatamab (dual‑HER2), bisTEs targeting CEA/CD3, and claudin‑18.2/CD47 agents like spevatamig — are paired with chemotherapy or checkpoint blockade to boost response rates while limiting systemic toxicity. Cellular therapies are maturing: CD40 agonists (Mitazalimab), armored T‑cells, and off‑the‑shelf NK platforms are being combined with standard regimens in pancreatic and gastric cancers, aiming to overcome immune‑cold microenvironments.

Together, earlier molecular selection, novel protein‑targeting strategies, and next‑generation immunotherapies promise a more personalized, potentially preventive cancer care landscape in 2026, aligning with Hirschfeld Oncology’s mission to blend cutting‑edge science with compassionate treatment.

Latest Advances for Stomach Cancer

Recent data from the 2026 ASCO Gastrointestinal Cancers Symposium show that stomach (gastric) cancer therapy is moving toward biomarker‑driven chemo‑immunotherapy combinations in both the neoadjuvant and adjuvant settings. In the neoadjuvant arena, the CRITICS‑II phase‑II trial compared three peri‑operative strategies and suggested that chemotherapy followed by chemoradiotherapy may improve outcomes for resectable gastric adenocarcinoma. Building on this, the ILUSTRO phase‑II study (LBA284) evaluated zolbetuximab (a CLDN18.2‑targeted antibody) together with mFOLFOX6 and nivolumab, achieving a median progression‑free survival of 12.9 months in CLDN18.2‑positive disease. HERIZON‑GEA‑01 (LBA285) demonstrated that zanidatamab, a bispecific anti‑HER2 antibody, plus chemotherapy with or without tislelizumab extended PFS beyond 12 months and reduced progression risk by 35 % versus trastuzumab‑based regimens in HER2‑positive gastroesophageal adenocarcinoma. In the adjuvant setting, the KEYNOTE‑937 phase‑III trial is testing pembrolizumab versus placebo after curative resection or ablation in hepatocellular carcinoma, and the CAPITAL trial is comparing oxaliplatin‑added S‑1 (SOX) to S‑1 alone for stage II‑III gastric cancer post‑D2 gastrectomy. Together, these studies illustrate a rapid shift toward integrating targeted antibodies (CLDN18.2, HER2) and immune checkpoint blockade with standard chemotherapy, offering a new standard of care that personalizes therapy based on tumor biology.

Looking Ahead: Personalized, Multi‑Agent Strategies

Biomarker testing is becoming the backbone of gastrointestinal oncology, guiding the selection of targeted agents, immunotherapies and novel degraders. At ASCO GI 2026, trials such as ILUSTRO, HERIZON‑GEA‑01 and INCB161734 demonstrated that CLDN18.2, HER2 and KRAS G12D status can predict response to combination regimens, underscoring the need for routine genomic profiling and ctDNA monitoring. Parallel to laboratory advances, patient participation in clinical trials remains the fastest route to bring these multi‑agent strategies to practice. Enrolling in adaptive, biomarker‑driven studies not only expands therapeutic options for individuals but also accelerates the generation of evidence that refines standards of care. Hirschfeld Oncology, led by Dr. Azriel Hirschfeld, exemplifies this paradigm. The center integrates standard chemotherapy with cutting‑edge agents—KRAS G12D inhibitors, CD40 agonists and bispecific antibodies—while actively recruiting patients for its pancreatic cancer trials, ensuring that every eligible individual can access the most innovative, evidence‑based treatments and improve long‑term survival outcomes for patients worldwide.